Revvity, Inc. (RVTY)

NYSE · Health Care · Diagnostics & Research
By Alex · Tickerpine
$124.84
+1.84 (+1.50%)
Price — last 10 years monthly, dividend-adjusted · hover for detail
Market Cap
$13.93B
P/E (TTM)
60.0
Forward P/E
21.2
EPS (TTM)
$2.08
ROE
3.21%
Profit Margin
8.16%
Revenue Growth
1.30%
Dividend Yield
0.22%
Beta
1.07
52W High
$124.97
52W Low
$81.22
Analyst Target
$121.07
What would an investment in RVTY be worth today?
Run RVTY through our free historical return calculator.
Calculate RVTY returns →

RVTY historical returns

PeriodTotal returnAnnualized (CAGR)$1,000 grew to
1 year +38.9% +39.0% $1,389
3 years +7.5% +2.5% $1,075
5 years -31.6% -7.3% $684
10 years +141% +9.2% $2,413
20 years +673% +10.8% $7,730
Since 1985 +2,344% +8.0% $24,444

Based on monthly dividend-adjusted prices. See the full breakdown on what if you had invested in RVTY.

RVTY annual returns by year

2026 YTD +29.3%
2025 -13.1%
2024 +2.4%
2023 -21.9%
2022 -30.1%
2021 +40.4%
2020 +48.2%
2019 +24.0%
2018 +7.8%
2017 +40.8%

Congress trading in RVTY

4 members of Congress have disclosed trading RVTY — 6 purchases and 1 sale worth an estimated $87,501. Most recent disclosure: May 4, 2026.

Insider activity in RVTY

RVTY's own executives and directors have made 0 open-market purchases ($0) and 1 sale ($9,306) in the last 90 days, per SEC Form 4 filings. Most recent: Jul 20, 2026.

Jul 20, 2026Gonzales Anita Vice President and CAO Sell $9,306

About Revvity, Inc.

Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray , EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

Company website ↗

RVTY Key Statistics

Previous Close$123.00P/E Ratio60.0
Market Cap$13.93BPEG Ratio0.77
Revenue (TTM)$2.91BROE3.21%
Gross Margin54.98%ROA2.37%
Debt / Equity46.2Employees11,000

RVTY in plain English

RVTY stock: frequently asked questions

What is Revvity, Inc.'s stock price today?

Revvity, Inc. (RVTY) last traded at $124.84 on the NYSE. Over the past 52 weeks the stock has traded between $81.22 and $124.97.

How much would $1,000 invested in RVTY 10 years ago be worth today?

A $1,000 investment in Revvity, Inc. made 10 years ago would be worth about $2,413 today (dividends reinvested) — a total return of 141%, or 9.2% per year.

Does RVTY pay a dividend?

Yes. Revvity, Inc. currently pays a dividend yielding about 0.22% per year at today's share price.

What is RVTY's P/E ratio?

RVTY trades at a trailing price-to-earnings ratio of 60.0, and 21.2 times expected forward earnings. The P/E ratio tells you how many dollars investors pay for each $1 of the company's annual profit.

Do members of Congress trade RVTY stock?

Yes — 4 members of Congress have disclosed trades in RVTY under the STOCK Act, totaling 6 purchases and 1 sales worth an estimated $87,501.

What is Revvity, Inc.'s ticker symbol?

Revvity, Inc. trades under the ticker symbol RVTY on the NYSE.

Compare RVTY with peers

RVTY vs LLYEli Lilly and Company $1,233.66 RVTY vs JNJJohnson & Johnson $273.14 RVTY vs ABBVAbbVie Inc. $265.79 RVTY vs MRKMerck & Co., Inc. $156.45 RVTY vs UNHUnitedHealth Group Incorporated $396.59

Data last refreshed from public sources. Figures may be delayed. Not investment advice.